OBJECTIVES: To determine the repeatability and response to therapy of dynamic contrast-enhanced (DCE) MRI biomarkers of @entity603 in the hand and wrist of @entity309 ( @entity309 ) @entity1 , and in particular the performance of the transfer constant @entity3529 (trans) , in a multicentre trial setting. METHODS: DCE-MRI and @entity309 MRI scoring (RAMRIS) were performed with meticulous standardisation at baseline and 6 and 24  weeks in a substudy of @entity30210 monotherapy in reducing @entity603 compared with placebo or adalimumab. Analysis employed statistical shape modelling to avoid biased regions-of-interest, kinetic modelling and heuristic analyses. Repeatability was also evaluated. RESULTS: At early study termination, DCE-MRI data had been acquired from 58 @entity1 in 19 imaging centres. @entity3529 (trans) intra-subject coefficient of variation (N   =   14) was 30%. @entity3529 (trans) change demonstrated inferiority of @entity30210 (N   =   11) relative to adalimumab (N   =   10) after 6  weeks (treatment ratio   =   1.92, p   =   0.003), and failed to distinguish @entity30210 from placebo (N   =   10, p   =   0.79). RAMRIS showed superiority of @entity30210 relative to placebo at 6  weeks (p   =   0.023), and did not distinguish @entity30210 from adalimumab at either 6 (p   =   0.175) or 24 (p   =   0.230) weeks. CONCLUSION: This demonstrated repeatability of @entity3529 (trans) and its ability to distinguish treatment groups show that DCE-MRI biomarkers are suitable for use in multicentre @entity309 trials. KEY POINTS:     DCE-MRI biomarkers are feasible in large multicentre studies of @entity32 .     DCE-MRI @entity3529 (trans) showed @entity30210 inferior to adalimumab after 6  weeks.     @entity3529 (trans) repeatability coefficient of variation was 30% multicentre.

Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in XXXX in a large multicentre trial setting.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['joint inflammation'] @entity3529 :: ('D011188', 'Chemical') :: ['K'] @entity603 :: ('MESH:D013585', 'Disease') :: ['synovitis'] @entity30210 :: ('MESH:C523665', 'Chemical') :: ['fostamatinib'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']
@entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']
